Zai Lab (NASDAQ:ZLAB) was downgraded by equities research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.
A number of other equities analysts have also commented on the stock. ValuEngine upgraded shares of Zai Lab from a “hold” rating to a “buy” rating in a report on Thursday, February 7th. Credit Suisse Group assumed coverage on shares of Zai Lab in a report on Tuesday, January 29th. They issued an “outperform” rating and a $34.70 target price on the stock. Zacks Investment Research upgraded shares of Zai Lab from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a report on Sunday, January 6th. Finally, Jefferies Financial Group assumed coverage on shares of Zai Lab in a report on Wednesday, November 21st. They issued a “buy” rating on the stock. Seven research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $33.93.
Shares of NASDAQ:ZLAB opened at $28.57 on Tuesday. The firm has a market cap of $1.78 billion, a PE ratio of -12.31 and a beta of 1.20. Zai Lab has a 52 week low of $14.29 and a 52 week high of $33.86.
Zai Lab Company Profile
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Recommended Story: LIBOR
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.